ALGERNON PHARMACEUTICALS INC News

Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF), a Canadian clinical stage pharmaceutical

GlobeNewswireApr 24 07:47 ET

Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024

Yahoo FinanceApr 11 07:00 ET

DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design

Canadian clinical-stage biotech company Algernon Pharmaceuticals (OTCQB:AGNPF) announced its plans to move forward with an intravenous (IV) formulation of its DMT-based compound AP-188 for the potenti

BenzingaApr 3 16:45 ET

Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatment

Yahoo FinanceMar 28 08:40 ET

Algernon Pharmaceuticals Announces Closing of the Acquisition of Its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF), a Canadian clinical stage pharmaceutical

GlobeNewswireMar 27 12:04 ET

Algernon Pharmaceuticals Announces Closing of Private Placement

VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF) (the "Company" or "Algernon") a Canadian clinical stage pharmaceutical development

GlobeNewswireDec 27, 2023 16:01 ET

Algernon Pharmaceuticals Increases Size of Private Placement

Seeking AlphaDec 27, 2023 07:50 ET

Algernon Pharmaceuticals Announces Private Placement

Seeking AlphaDec 13, 2023 02:57 ET

Algernon Pharmaceuticals Announces LOI for the Acquisition of Its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF), a Canadian clinical stage pharmaceutical development

GlobeNewswireNov 22, 2023 07:00 ET

Algernon Gets Japanese Patent Notice of Allowance for Treatment of NASH With Repirinast

Seeking AlphaNov 8, 2023 07:18 ET

Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published The American Psychedelic Practitioners Association (APPA) and BrainFutures have published the first-ever set of p

BenzingaAug 14, 2023 09:46 ET

FibroGen Drives Scholar Rock, Omega Lower After Setback for Lung Disease Candidate

Seeking AlphaJun 26, 2023 13:34 ET

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage ph

GlobeNewswireJun 5, 2023 07:00 ET

Algernon Pharmaceuticals Announces Closing of Rights Offering

VANCOUVER, British Columbia, May 05, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the "Company" or "Algernon") a Canadian clinical stage pharma

GlobeNewswireMay 5, 2023 17:05 ET

Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Short Interest Up 13.4% in April

Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF – Get Rating) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totalling 33,100 shares, an

Defense WorldApr 30, 2023 02:23 ET

CSE Bulletin: Expiry - Algernon Pharmaceuticals Inc. - Rights (AGN.RT)

Toronto, Ontario--(Newsfile Corp. - le 21 avril/April 2023) - Algernon Pharmaceuticals Inc. Rights listed on March 28, 2023 will expire on April 27, 2023. Settlement Terms: All trades April 25 and 26

newsfileApr 21, 2023 14:35 ET

Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time

VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutic

GlobeNewswireApr 20, 2023 07:11 ET

How To Finance A Psychedelics Business? Learn From These Four Companies

Clearmind Medicine Announces Pricing of $3.5 Million Public Offering Israeli biotech company Clearmind Medicine Inc. (NASDAQ:CMND) announced the pricing of its US-only public offering of 4.6 million c

BenzingaApr 4, 2023 16:42 ET

Intravenous DMT Therapy Seeks Ideal Dosage For Stroke And TBI Treatment

Canadian biopharma company Algernon Pharmaceuticals Inc. (OTCQB:AGNPF)'s subsidiary Algernon NeuroScience (AGN Neuro) completed dosing the second cohort of its Phase 1 study on the company's proprieta

BenzingaApr 4, 2023 14:27 ET

Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study

VANCOUVER, British Columbia, April 04, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage p

GlobeNewswireApr 4, 2023 07:06 ET